nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—TEK—sarcoma	0.158	0.293	CbGaD
Vandetanib—PDGFRB—sarcoma	0.102	0.189	CbGaD
Vandetanib—SRC—sarcoma	0.0821	0.152	CbGaD
Vandetanib—KDR—sarcoma	0.0771	0.143	CbGaD
Vandetanib—VEGFA—sarcoma	0.0654	0.121	CbGaD
Vandetanib—EGFR—sarcoma	0.0552	0.102	CbGaD
Vandetanib—ABCC1—Dactinomycin—sarcoma	0.0278	0.14	CbGbCtD
Vandetanib—ABCC1—Mitoxantrone—sarcoma	0.0249	0.125	CbGbCtD
Vandetanib—ABCC1—Epirubicin—sarcoma	0.0202	0.101	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—sarcoma	0.0186	0.0935	CbGbCtD
Vandetanib—ABCC1—Vincristine—sarcoma	0.0171	0.0861	CbGbCtD
Vandetanib—ABCG2—Mitoxantrone—sarcoma	0.0167	0.0837	CbGbCtD
Vandetanib—ABCC1—Etoposide—sarcoma	0.0157	0.0789	CbGbCtD
Vandetanib—ABCG2—Vincristine—sarcoma	0.0115	0.0576	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—sarcoma	0.0107	0.0538	CbGbCtD
Vandetanib—ABCG2—Etoposide—sarcoma	0.0105	0.0528	CbGbCtD
Vandetanib—CYP3A4—Thiotepa—sarcoma	0.00838	0.042	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—sarcoma	0.00717	0.036	CbGbCtD
Vandetanib—CYP3A4—Mitoxantrone—sarcoma	0.0036	0.0181	CbGbCtD
Vandetanib—CYP3A4—Vincristine—sarcoma	0.00248	0.0124	CbGbCtD
Vandetanib—CYP3A4—Etoposide—sarcoma	0.00227	0.0114	CbGbCtD
Vandetanib—CYP3A4—Doxorubicin—sarcoma	0.00155	0.00778	CbGbCtD
Vandetanib—Afatinib—EGFR—sarcoma	0.000825	0.248	CrCbGaD
Vandetanib—Bosutinib—PDGFRB—sarcoma	0.000663	0.199	CrCbGaD
Vandetanib—Erlotinib—EGFR—sarcoma	0.000583	0.175	CrCbGaD
Vandetanib—Bosutinib—SRC—sarcoma	0.000534	0.161	CrCbGaD
Vandetanib—ERBB3—Podofilox—Etoposide—sarcoma	0.000382	0.168	CbGdCrCtD
Vandetanib—Gefitinib—EGFR—sarcoma	0.000365	0.11	CrCbGaD
Vandetanib—Bosutinib—EGFR—sarcoma	0.000359	0.108	CrCbGaD
Vandetanib—PLK4—Teniposide—Etoposide—sarcoma	0.000293	0.129	CbGdCrCtD
Vandetanib—ERBB3—Vinblastine—Vincristine—sarcoma	0.000263	0.116	CbGdCrCtD
Vandetanib—STK10—myometrium—sarcoma	0.00025	0.00364	CbGeAlD
Vandetanib—RET—connective tissue—sarcoma	0.000248	0.00361	CbGeAlD
Vandetanib—AXL—connective tissue—sarcoma	0.000247	0.0036	CbGeAlD
Vandetanib—MAP4K5—seminal vesicle—sarcoma	0.000246	0.0036	CbGeAlD
Vandetanib—ABL1—mammary gland—sarcoma	0.000242	0.00354	CbGeAlD
Vandetanib—ERBB3—skin of body—sarcoma	0.000241	0.00352	CbGeAlD
Vandetanib—FYN—hematopoietic system—sarcoma	0.00024	0.0035	CbGeAlD
Vandetanib—STK35—cardiac atrium—sarcoma	0.000239	0.00348	CbGeAlD
Vandetanib—EPHB6—seminal vesicle—sarcoma	0.000236	0.00344	CbGeAlD
Vandetanib—TEK—hematopoietic system—sarcoma	0.000234	0.00342	CbGeAlD
Vandetanib—MAP4K5—hematopoietic system—sarcoma	0.000234	0.00342	CbGeAlD
Vandetanib—SRC—embryo—sarcoma	0.000233	0.0034	CbGeAlD
Vandetanib—FYN—connective tissue—sarcoma	0.000231	0.00337	CbGeAlD
Vandetanib—YES1—seminal vesicle—sarcoma	0.000228	0.00332	CbGeAlD
Vandetanib—FLT3—lymphoid tissue—sarcoma	0.000226	0.00329	CbGeAlD
Vandetanib—EGFR—uterus—sarcoma	0.000226	0.00329	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—sarcoma	0.000226	0.00329	CbGeAlD
Vandetanib—TEK—connective tissue—sarcoma	0.000226	0.00329	CbGeAlD
Vandetanib—ALB—mammary gland—sarcoma	0.000224	0.00326	CbGeAlD
Vandetanib—KDR—myometrium—sarcoma	0.000223	0.00325	CbGeAlD
Vandetanib—MAP2K5—myometrium—sarcoma	0.000223	0.00325	CbGeAlD
Vandetanib—EPHA6—testis—sarcoma	0.000223	0.00325	CbGeAlD
Vandetanib—AXL—skin of body—sarcoma	0.000223	0.00325	CbGeAlD
Vandetanib—PLK4—testis—sarcoma	0.00022	0.00321	CbGeAlD
Vandetanib—RIPK2—cardiac atrium—sarcoma	0.00022	0.00321	CbGeAlD
Vandetanib—VEGFA—cardiac atrium—sarcoma	0.000219	0.0032	CbGeAlD
Vandetanib—VEGFA—uterus—sarcoma	0.000218	0.00318	CbGeAlD
Vandetanib—YES1—hematopoietic system—sarcoma	0.000216	0.00316	CbGeAlD
Vandetanib—KDR—embryo—sarcoma	0.000214	0.00313	CbGeAlD
Vandetanib—STK10—hematopoietic system—sarcoma	0.000214	0.00313	CbGeAlD
Vandetanib—FYN—smooth muscle tissue—sarcoma	0.000211	0.00308	CbGeAlD
Vandetanib—ERBB3—uterus—sarcoma	0.000209	0.00306	CbGeAlD
Vandetanib—FYN—skin of body—sarcoma	0.000208	0.00304	CbGeAlD
Vandetanib—YES1—connective tissue—sarcoma	0.000208	0.00304	CbGeAlD
Vandetanib—SRC—hematopoietic system—sarcoma	0.000208	0.00304	CbGeAlD
Vandetanib—STK35—tendon—sarcoma	0.000208	0.00303	CbGeAlD
Vandetanib—TYRO3—testis—sarcoma	0.000207	0.00301	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—sarcoma	0.000206	0.00301	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—sarcoma	0.000206	0.00301	CbGeAlD
Vandetanib—FLT3—bone marrow—sarcoma	0.000206	0.003	CbGeAlD
Vandetanib—FLT4—lymphoid tissue—sarcoma	0.000205	0.00299	CbGeAlD
Vandetanib—BLK—lymph node—sarcoma	0.000204	0.00298	CbGeAlD
Vandetanib—ABL2—tendon—sarcoma	0.000203	0.00296	CbGeAlD
Vandetanib—BMPR1B—testis—sarcoma	0.000202	0.00295	CbGeAlD
Vandetanib—MAP3K19—testis—sarcoma	0.000202	0.00295	CbGeAlD
Vandetanib—LTK—lymph node—sarcoma	0.000202	0.00295	CbGeAlD
Vandetanib—MAP2K5—seminal vesicle—sarcoma	0.000201	0.00294	CbGeAlD
Vandetanib—KDR—seminal vesicle—sarcoma	0.000201	0.00294	CbGeAlD
Vandetanib—SRC—connective tissue—sarcoma	0.0002	0.00292	CbGeAlD
Vandetanib—IRAK4—lymphoid tissue—sarcoma	0.000199	0.0029	CbGeAlD
Vandetanib—MKNK1—cardiac atrium—sarcoma	0.000198	0.00288	CbGeAlD
Vandetanib—ERBB3—lymphoid tissue—sarcoma	0.000195	0.00285	CbGeAlD
Vandetanib—EPHB6—skin of body—sarcoma	0.000195	0.00284	CbGeAlD
Vandetanib—AXL—cardiac atrium—sarcoma	0.000194	0.00284	CbGeAlD
Vandetanib—LYN—liver—sarcoma	0.000194	0.00284	CbGeAlD
Vandetanib—LCK—uterus—sarcoma	0.000194	0.00283	CbGeAlD
Vandetanib—AXL—uterus—sarcoma	0.000193	0.00282	CbGeAlD
Vandetanib—PDGFRB—myometrium—sarcoma	0.000193	0.00281	CbGeAlD
Vandetanib—RIPK2—tendon—sarcoma	0.000192	0.0028	CbGeAlD
Vandetanib—KDR—hematopoietic system—sarcoma	0.000191	0.00279	CbGeAlD
Vandetanib—VEGFA—tendon—sarcoma	0.000191	0.00279	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—sarcoma	0.000191	0.00278	CbGeAlD
Vandetanib—FMO1—tendon—sarcoma	0.00019	0.00277	CbGeAlD
Vandetanib—IRAK4—tendon—sarcoma	0.000187	0.00273	CbGeAlD
Vandetanib—SLK—cardiac atrium—sarcoma	0.000187	0.00273	CbGeAlD
Vandetanib—FLT4—bone marrow—sarcoma	0.000187	0.00272	CbGeAlD
Vandetanib—SLK—uterus—sarcoma	0.000186	0.00272	CbGeAlD
Vandetanib—RIPK2—bone marrow—sarcoma	0.000186	0.00271	CbGeAlD
Vandetanib—PDGFRB—embryo—sarcoma	0.000186	0.00271	CbGeAlD
Vandetanib—VEGFA—bone marrow—sarcoma	0.000185	0.0027	CbGeAlD
Vandetanib—KDR—connective tissue—sarcoma	0.000184	0.00269	CbGeAlD
Vandetanib—SRC—smooth muscle tissue—sarcoma	0.000183	0.00267	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—sarcoma	0.000183	0.00267	CbGeAlD
Vandetanib—FYN—cardiac atrium—sarcoma	0.000182	0.00265	CbGeAlD
Vandetanib—IRAK4—bone marrow—sarcoma	0.000181	0.00265	CbGeAlD
Vandetanib—FYN—uterus—sarcoma	0.000181	0.00264	CbGeAlD
Vandetanib—RET—lymphoid tissue—sarcoma	0.000181	0.00264	CbGeAlD
Vandetanib—FGR—lymphoid tissue—sarcoma	0.000181	0.00264	CbGeAlD
Vandetanib—SRC—skin of body—sarcoma	0.000181	0.00264	CbGeAlD
Vandetanib—AXL—lymphoid tissue—sarcoma	0.00018	0.00263	CbGeAlD
Vandetanib—MAP4K5—cardiac atrium—sarcoma	0.000178	0.00259	CbGeAlD
Vandetanib—TEK—cardiac atrium—sarcoma	0.000178	0.00259	CbGeAlD
Vandetanib—MAP4K5—uterus—sarcoma	0.000177	0.00258	CbGeAlD
Vandetanib—TEK—uterus—sarcoma	0.000177	0.00258	CbGeAlD
Vandetanib—FLT3—testis—sarcoma	0.000176	0.00256	CbGeAlD
Vandetanib—PDGFRB—seminal vesicle—sarcoma	0.000174	0.00254	CbGeAlD
Vandetanib—STK35—testis—sarcoma	0.000172	0.00251	CbGeAlD
Vandetanib—ABL1—myometrium—sarcoma	0.000172	0.00251	CbGeAlD
Vandetanib—FGR—tendon—sarcoma	0.00017	0.00248	CbGeAlD
Vandetanib—RET—tendon—sarcoma	0.00017	0.00248	CbGeAlD
Vandetanib—EPHB6—cardiac atrium—sarcoma	0.00017	0.00248	CbGeAlD
Vandetanib—AXL—tendon—sarcoma	0.000169	0.00247	CbGeAlD
Vandetanib—FYN—lymphoid tissue—sarcoma	0.000169	0.00246	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—sarcoma	0.000169	0.00246	CbGeAlD
Vandetanib—ABL2—testis—sarcoma	0.000168	0.00245	CbGeAlD
Vandetanib—MKNK1—bone marrow—sarcoma	0.000167	0.00243	CbGeAlD
Vandetanib—FLT3—liver—sarcoma	0.000166	0.00242	CbGeAlD
Vandetanib—PDGFRB—hematopoietic system—sarcoma	0.000166	0.00242	CbGeAlD
Vandetanib—ABL1—embryo—sarcoma	0.000165	0.00241	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—sarcoma	0.000165	0.00241	CbGeAlD
Vandetanib—TEK—lymphoid tissue—sarcoma	0.000165	0.00241	CbGeAlD
Vandetanib—FGR—bone marrow—sarcoma	0.000165	0.0024	CbGeAlD
Vandetanib—LCK—bone marrow—sarcoma	0.000165	0.0024	CbGeAlD
Vandetanib—YES1—cardiac atrium—sarcoma	0.000164	0.0024	CbGeAlD
Vandetanib—EGFR—testis—sarcoma	0.000164	0.00239	CbGeAlD
Vandetanib—YES1—uterus—sarcoma	0.000163	0.00238	CbGeAlD
Vandetanib—SLK—tendon—sarcoma	0.000163	0.00238	CbGeAlD
Vandetanib—STK35—liver—sarcoma	0.000163	0.00237	CbGeAlD
Vandetanib—STK10—uterus—sarcoma	0.000162	0.00236	CbGeAlD
Vandetanib—FLT4—testis—sarcoma	0.00016	0.00233	CbGeAlD
Vandetanib—PDGFRB—connective tissue—sarcoma	0.00016	0.00233	CbGeAlD
Vandetanib—PLK4—lymph node—sarcoma	0.000159	0.00233	CbGeAlD
Vandetanib—RIPK2—testis—sarcoma	0.000159	0.00232	CbGeAlD
Vandetanib—FYN—tendon—sarcoma	0.000159	0.00231	CbGeAlD
Vandetanib—ABL2—liver—sarcoma	0.000159	0.00231	CbGeAlD
Vandetanib—VEGFA—testis—sarcoma	0.000158	0.00231	CbGeAlD
Vandetanib—SLK—bone marrow—sarcoma	0.000158	0.00231	CbGeAlD
Vandetanib—SRC—cardiac atrium—sarcoma	0.000158	0.00231	CbGeAlD
Vandetanib—ORM1—hematopoietic system—sarcoma	0.000155	0.00227	CbGeAlD
Vandetanib—ABL1—seminal vesicle—sarcoma	0.000155	0.00227	CbGeAlD
Vandetanib—MAP4K5—tendon—sarcoma	0.000155	0.00226	CbGeAlD
Vandetanib—TEK—tendon—sarcoma	0.000155	0.00226	CbGeAlD
Vandetanib—IRAK4—testis—sarcoma	0.000155	0.00226	CbGeAlD
Vandetanib—EGFR—liver—sarcoma	0.000155	0.00226	CbGeAlD
Vandetanib—FYN—bone marrow—sarcoma	0.000154	0.00224	CbGeAlD
Vandetanib—PLK4—Idarubicin—Epirubicin—sarcoma	0.000153	0.0673	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Epirubicin—sarcoma	0.000153	0.0673	CbGdCrCtD
Vandetanib—YES1—lymphoid tissue—sarcoma	0.000152	0.00222	CbGeAlD
Vandetanib—ERBB3—testis—sarcoma	0.000152	0.00222	CbGeAlD
Vandetanib—STK10—lymphoid tissue—sarcoma	0.000151	0.0022	CbGeAlD
Vandetanib—FLT4—liver—sarcoma	0.000151	0.0022	CbGeAlD
Vandetanib—MAP4K5—bone marrow—sarcoma	0.00015	0.00219	CbGeAlD
Vandetanib—RIPK2—liver—sarcoma	0.00015	0.00219	CbGeAlD
Vandetanib—VEGFA—liver—sarcoma	0.00015	0.00218	CbGeAlD
Vandetanib—FMO1—liver—sarcoma	0.000149	0.00217	CbGeAlD
Vandetanib—EPHB6—tendon—sarcoma	0.000148	0.00216	CbGeAlD
Vandetanib—ABL1—hematopoietic system—sarcoma	0.000148	0.00215	CbGeAlD
Vandetanib—BMPR1B—lymph node—sarcoma	0.000147	0.00214	CbGeAlD
Vandetanib—IRAK4—liver—sarcoma	0.000147	0.00214	CbGeAlD
Vandetanib—SRC—lymphoid tissue—sarcoma	0.000147	0.00214	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—sarcoma	0.000146	0.00213	CbGeAlD
Vandetanib—KDR—cardiac atrium—sarcoma	0.000145	0.00212	CbGeAlD
Vandetanib—MAP2K5—cardiac atrium—sarcoma	0.000145	0.00212	CbGeAlD
Vandetanib—KDR—uterus—sarcoma	0.000145	0.00211	CbGeAlD
Vandetanib—PDGFRB—skin of body—sarcoma	0.000144	0.0021	CbGeAlD
Vandetanib—ERBB3—liver—sarcoma	0.000144	0.0021	CbGeAlD
Vandetanib—YES1—tendon—sarcoma	0.000143	0.00209	CbGeAlD
Vandetanib—MKNK1—testis—sarcoma	0.000143	0.00208	CbGeAlD
Vandetanib—ABL1—connective tissue—sarcoma	0.000142	0.00207	CbGeAlD
Vandetanib—STK10—tendon—sarcoma	0.000142	0.00207	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—sarcoma	0.000141	0.0623	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—sarcoma	0.000141	0.0623	CbGdCrCtD
Vandetanib—FGR—testis—sarcoma	0.000141	0.00206	CbGeAlD
Vandetanib—LCK—testis—sarcoma	0.000141	0.00206	CbGeAlD
Vandetanib—RET—testis—sarcoma	0.000141	0.00206	CbGeAlD
Vandetanib—AXL—testis—sarcoma	0.00014	0.00205	CbGeAlD
Vandetanib—YES1—bone marrow—sarcoma	0.000139	0.00202	CbGeAlD
Vandetanib—STK10—bone marrow—sarcoma	0.000137	0.002	CbGeAlD
Vandetanib—FMO3—testis—sarcoma	0.000136	0.00199	CbGeAlD
Vandetanib—SLK—testis—sarcoma	0.000135	0.00197	CbGeAlD
Vandetanib—MKNK1—liver—sarcoma	0.000135	0.00197	CbGeAlD
Vandetanib—KDR—lymphoid tissue—sarcoma	0.000135	0.00197	CbGeAlD
Vandetanib—LCK—liver—sarcoma	0.000133	0.00194	CbGeAlD
Vandetanib—FGR—liver—sarcoma	0.000133	0.00194	CbGeAlD
Vandetanib—AXL—liver—sarcoma	0.000133	0.00194	CbGeAlD
Vandetanib—FYN—testis—sarcoma	0.000131	0.00192	CbGeAlD
Vandetanib—ABCC1—myometrium—sarcoma	0.000131	0.00191	CbGeAlD
Vandetanib—ABL1—smooth muscle tissue—sarcoma	0.00013	0.0019	CbGeAlD
Vandetanib—FMO3—liver—sarcoma	0.000129	0.00188	CbGeAlD
Vandetanib—ABL1—Idarubicin—Epirubicin—sarcoma	0.000129	0.0566	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Epirubicin—sarcoma	0.000129	0.0566	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—sarcoma	0.000129	0.0566	CbGdCrCtD
Vandetanib—ABL1—skin of body—sarcoma	0.000128	0.00187	CbGeAlD
Vandetanib—TEK—testis—sarcoma	0.000128	0.00187	CbGeAlD
Vandetanib—MAP4K5—testis—sarcoma	0.000128	0.00187	CbGeAlD
Vandetanib—SLK—liver—sarcoma	0.000128	0.00186	CbGeAlD
Vandetanib—FLT3—lymph node—sarcoma	0.000127	0.00186	CbGeAlD
Vandetanib—KDR—tendon—sarcoma	0.000127	0.00185	CbGeAlD
Vandetanib—MAP2K5—tendon—sarcoma	0.000127	0.00185	CbGeAlD
Vandetanib—PDGFRB—cardiac atrium—sarcoma	0.000126	0.00184	CbGeAlD
Vandetanib—PDGFRB—uterus—sarcoma	0.000125	0.00183	CbGeAlD
Vandetanib—STK35—lymph node—sarcoma	0.000125	0.00182	CbGeAlD
Vandetanib—FYN—liver—sarcoma	0.000124	0.00181	CbGeAlD
Vandetanib—KDR—bone marrow—sarcoma	0.000123	0.00179	CbGeAlD
Vandetanib—EPHB6—testis—sarcoma	0.000123	0.00179	CbGeAlD
Vandetanib—ABL2—lymph node—sarcoma	0.000122	0.00177	CbGeAlD
Vandetanib—MAP4K5—liver—sarcoma	0.000121	0.00177	CbGeAlD
Vandetanib—TEK—liver—sarcoma	0.000121	0.00177	CbGeAlD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—sarcoma	0.000119	0.0524	CbGdCrCtD
Vandetanib—ABL1—Epirubicin—Doxorubicin—sarcoma	0.000119	0.0524	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—sarcoma	0.000119	0.0524	CbGdCrCtD
Vandetanib—EGFR—lymph node—sarcoma	0.000119	0.00173	CbGeAlD
Vandetanib—YES1—testis—sarcoma	0.000119	0.00173	CbGeAlD
Vandetanib—ABCC1—seminal vesicle—sarcoma	0.000118	0.00173	CbGeAlD
Vandetanib—STK10—testis—sarcoma	0.000117	0.00171	CbGeAlD
Vandetanib—PDGFRB—lymphoid tissue—sarcoma	0.000117	0.0017	CbGeAlD
Vandetanib—FLT4—lymph node—sarcoma	0.000116	0.00169	CbGeAlD
Vandetanib—RIPK2—lymph node—sarcoma	0.000115	0.00168	CbGeAlD
Vandetanib—VEGFA—lymph node—sarcoma	0.000115	0.00167	CbGeAlD
Vandetanib—FMO1—lymph node—sarcoma	0.000114	0.00166	CbGeAlD
Vandetanib—SRC—testis—sarcoma	0.000114	0.00166	CbGeAlD
Vandetanib—IRAK4—lymph node—sarcoma	0.000112	0.00164	CbGeAlD
Vandetanib—ABL1—cardiac atrium—sarcoma	0.000112	0.00164	CbGeAlD
Vandetanib—YES1—liver—sarcoma	0.000112	0.00163	CbGeAlD
Vandetanib—ABL1—uterus—sarcoma	0.000112	0.00163	CbGeAlD
Vandetanib—STK10—liver—sarcoma	0.000111	0.00162	CbGeAlD
Vandetanib—ERBB3—lymph node—sarcoma	0.00011	0.00161	CbGeAlD
Vandetanib—PDGFRB—tendon—sarcoma	0.00011	0.0016	CbGeAlD
Vandetanib—ABCG2—myometrium—sarcoma	0.000108	0.00158	CbGeAlD
Vandetanib—SRC—liver—sarcoma	0.000108	0.00157	CbGeAlD
Vandetanib—PDGFRB—bone marrow—sarcoma	0.000106	0.00155	CbGeAlD
Vandetanib—MAP2K5—testis—sarcoma	0.000105	0.00153	CbGeAlD
Vandetanib—KDR—testis—sarcoma	0.000105	0.00153	CbGeAlD
Vandetanib—ABL1—lymphoid tissue—sarcoma	0.000104	0.00152	CbGeAlD
Vandetanib—MKNK1—lymph node—sarcoma	0.000103	0.00151	CbGeAlD
Vandetanib—RET—lymph node—sarcoma	0.000102	0.00149	CbGeAlD
Vandetanib—LCK—lymph node—sarcoma	0.000102	0.00149	CbGeAlD
Vandetanib—FGR—lymph node—sarcoma	0.000102	0.00149	CbGeAlD
Vandetanib—AXL—lymph node—sarcoma	0.000102	0.00148	CbGeAlD
Vandetanib—ORM1—bone marrow—sarcoma	9.96e-05	0.00145	CbGeAlD
Vandetanib—KDR—liver—sarcoma	9.92e-05	0.00145	CbGeAlD
Vandetanib—MAP2K5—liver—sarcoma	9.92e-05	0.00145	CbGeAlD
Vandetanib—FMO3—lymph node—sarcoma	9.86e-05	0.00144	CbGeAlD
Vandetanib—ABCG2—seminal vesicle—sarcoma	9.8e-05	0.00143	CbGeAlD
Vandetanib—SLK—lymph node—sarcoma	9.79e-05	0.00143	CbGeAlD
Vandetanib—ABL1—tendon—sarcoma	9.77e-05	0.00143	CbGeAlD
Vandetanib—FYN—lymph node—sarcoma	9.52e-05	0.00139	CbGeAlD
Vandetanib—ABL1—bone marrow—sarcoma	9.47e-05	0.00138	CbGeAlD
Vandetanib—MAP4K5—lymph node—sarcoma	9.3e-05	0.00136	CbGeAlD
Vandetanib—TEK—lymph node—sarcoma	9.3e-05	0.00136	CbGeAlD
Vandetanib—PDGFRB—testis—sarcoma	9.08e-05	0.00132	CbGeAlD
Vandetanib—EPHB6—lymph node—sarcoma	8.89e-05	0.0013	CbGeAlD
Vandetanib—YES1—lymph node—sarcoma	8.59e-05	0.00125	CbGeAlD
Vandetanib—PDGFRB—liver—sarcoma	8.58e-05	0.00125	CbGeAlD
Vandetanib—ABCC1—cardiac atrium—sarcoma	8.54e-05	0.00125	CbGeAlD
Vandetanib—STK10—lymph node—sarcoma	8.51e-05	0.00124	CbGeAlD
Vandetanib—ABCC1—uterus—sarcoma	8.5e-05	0.00124	CbGeAlD
Vandetanib—SRC—lymph node—sarcoma	8.27e-05	0.00121	CbGeAlD
Vandetanib—Cardiac arrest—Epirubicin—sarcoma	8.26e-05	0.00124	CcSEcCtD
Vandetanib—Cardiac failure—Doxorubicin—sarcoma	8.23e-05	0.00123	CcSEcCtD
Vandetanib—Hypoglycaemia—Doxorubicin—sarcoma	8.23e-05	0.00123	CcSEcCtD
Vandetanib—Paraesthesia—Mitoxantrone—sarcoma	8.22e-05	0.00123	CcSEcCtD
Vandetanib—Loss of consciousness—Etoposide—sarcoma	8.2e-05	0.00123	CcSEcCtD
Vandetanib—Lethargy—Doxorubicin—sarcoma	8.2e-05	0.00123	CcSEcCtD
Vandetanib—Decreased appetite—Vincristine—sarcoma	8.17e-05	0.00122	CcSEcCtD
Vandetanib—Dyspnoea—Mitoxantrone—sarcoma	8.16e-05	0.00122	CcSEcCtD
Vandetanib—Cough—Etoposide—sarcoma	8.14e-05	0.00122	CcSEcCtD
Vandetanib—Blood creatinine increased—Epirubicin—sarcoma	8.13e-05	0.00122	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Vincristine—sarcoma	8.11e-05	0.00122	CcSEcCtD
Vandetanib—Fatigue—Vincristine—sarcoma	8.1e-05	0.00121	CcSEcCtD
Vandetanib—ABL1—testis—sarcoma	8.09e-05	0.00118	CbGeAlD
Vandetanib—Convulsion—Etoposide—sarcoma	8.08e-05	0.00121	CcSEcCtD
Vandetanib—Dehydration—Epirubicin—sarcoma	8.07e-05	0.00121	CcSEcCtD
Vandetanib—Hyponatraemia—Doxorubicin—sarcoma	8.07e-05	0.00121	CcSEcCtD
Vandetanib—Dyspepsia—Mitoxantrone—sarcoma	8.06e-05	0.00121	CcSEcCtD
Vandetanib—Hypertension—Etoposide—sarcoma	8.05e-05	0.00121	CcSEcCtD
Vandetanib—ORM1—liver—sarcoma	8.05e-05	0.00117	CbGeAlD
Vandetanib—Pain—Vincristine—sarcoma	8.04e-05	0.0012	CcSEcCtD
Vandetanib—Constipation—Vincristine—sarcoma	8.04e-05	0.0012	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	8.03e-05	0.0012	CcSEcCtD
Vandetanib—Dry skin—Epirubicin—sarcoma	7.96e-05	0.00119	CcSEcCtD
Vandetanib—Decreased appetite—Mitoxantrone—sarcoma	7.96e-05	0.00119	CcSEcCtD
Vandetanib—Chest pain—Etoposide—sarcoma	7.94e-05	0.00119	CcSEcCtD
Vandetanib—Hypokalaemia—Epirubicin—sarcoma	7.9e-05	0.00118	CcSEcCtD
Vandetanib—Fatigue—Mitoxantrone—sarcoma	7.89e-05	0.00118	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	7.89e-05	0.00118	CcSEcCtD
Vandetanib—Pain—Mitoxantrone—sarcoma	7.83e-05	0.00117	CcSEcCtD
Vandetanib—Constipation—Mitoxantrone—sarcoma	7.83e-05	0.00117	CcSEcCtD
Vandetanib—Nasopharyngitis—Epirubicin—sarcoma	7.76e-05	0.00116	CcSEcCtD
Vandetanib—Gastrointestinal pain—Vincristine—sarcoma	7.68e-05	0.00115	CcSEcCtD
Vandetanib—Gastritis—Epirubicin—sarcoma	7.68e-05	0.00115	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Epirubicin—sarcoma	7.66e-05	0.00115	CcSEcCtD
Vandetanib—ABL1—liver—sarcoma	7.65e-05	0.00112	CbGeAlD
Vandetanib—Cardiac arrest—Doxorubicin—sarcoma	7.64e-05	0.00115	CcSEcCtD
Vandetanib—KDR—lymph node—sarcoma	7.6e-05	0.00111	CbGeAlD
Vandetanib—MAP2K5—lymph node—sarcoma	7.6e-05	0.00111	CbGeAlD
Vandetanib—Asthenia—Thiotepa—sarcoma	7.6e-05	0.00114	CcSEcCtD
Vandetanib—Infection—Etoposide—sarcoma	7.56e-05	0.00113	CcSEcCtD
Vandetanib—Asthenia—Dactinomycin—sarcoma	7.55e-05	0.00113	CcSEcCtD
Vandetanib—Blood creatinine increased—Doxorubicin—sarcoma	7.53e-05	0.00113	CcSEcCtD
Vandetanib—Influenza—Epirubicin—sarcoma	7.5e-05	0.00113	CcSEcCtD
Vandetanib—Dysphagia—Epirubicin—sarcoma	7.5e-05	0.00113	CcSEcCtD
Vandetanib—Pruritus—Thiotepa—sarcoma	7.5e-05	0.00112	CcSEcCtD
Vandetanib—Gastrointestinal pain—Mitoxantrone—sarcoma	7.48e-05	0.00112	CcSEcCtD
Vandetanib—Dehydration—Doxorubicin—sarcoma	7.47e-05	0.00112	CcSEcCtD
Vandetanib—ALB—testis—sarcoma	7.47e-05	0.00109	CbGeAlD
Vandetanib—Thrombocytopenia—Etoposide—sarcoma	7.45e-05	0.00112	CcSEcCtD
Vandetanib—ABCC1—tendon—sarcoma	7.44e-05	0.00109	CbGeAlD
Vandetanib—Body temperature increased—Vincristine—sarcoma	7.43e-05	0.00111	CcSEcCtD
Vandetanib—Abdominal pain—Vincristine—sarcoma	7.43e-05	0.00111	CcSEcCtD
Vandetanib—Skin disorder—Etoposide—sarcoma	7.39e-05	0.00111	CcSEcCtD
Vandetanib—Dry skin—Doxorubicin—sarcoma	7.36e-05	0.0011	CcSEcCtD
Vandetanib—Pancreatitis—Epirubicin—sarcoma	7.36e-05	0.0011	CcSEcCtD
Vandetanib—Hypokalaemia—Doxorubicin—sarcoma	7.31e-05	0.0011	CcSEcCtD
Vandetanib—Diarrhoea—Thiotepa—sarcoma	7.25e-05	0.00109	CcSEcCtD
Vandetanib—Body temperature increased—Mitoxantrone—sarcoma	7.23e-05	0.00108	CcSEcCtD
Vandetanib—Abdominal pain—Mitoxantrone—sarcoma	7.23e-05	0.00108	CcSEcCtD
Vandetanib—Bronchitis—Epirubicin—sarcoma	7.22e-05	0.00108	CcSEcCtD
Vandetanib—Diarrhoea—Dactinomycin—sarcoma	7.2e-05	0.00108	CcSEcCtD
Vandetanib—Nasopharyngitis—Doxorubicin—sarcoma	7.18e-05	0.00108	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—sarcoma	7.11e-05	0.00107	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—sarcoma	7.09e-05	0.00106	CcSEcCtD
Vandetanib—ALB—liver—sarcoma	7.06e-05	0.00103	CbGeAlD
Vandetanib—ABCG2—uterus—sarcoma	7.03e-05	0.00103	CbGeAlD
Vandetanib—Neutropenia—Epirubicin—sarcoma	7.02e-05	0.00105	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—sarcoma	7.02e-05	0.00105	CcSEcCtD
Vandetanib—Dizziness—Thiotepa—sarcoma	7.01e-05	0.00105	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—sarcoma	6.97e-05	0.00105	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—sarcoma	6.94e-05	0.00104	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—sarcoma	6.94e-05	0.00104	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—sarcoma	6.93e-05	0.00104	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—sarcoma	6.85e-05	0.00103	CcSEcCtD
Vandetanib—Paraesthesia—Etoposide—sarcoma	6.84e-05	0.00102	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—sarcoma	6.81e-05	0.00102	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—sarcoma	6.79e-05	0.00102	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—sarcoma	6.79e-05	0.00102	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—sarcoma	6.77e-05	0.00101	CcSEcCtD
Vandetanib—Asthenia—Vincristine—sarcoma	6.74e-05	0.00101	CcSEcCtD
Vandetanib—Vomiting—Thiotepa—sarcoma	6.74e-05	0.00101	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—sarcoma	6.73e-05	0.00101	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—sarcoma	6.69e-05	0.001	CcSEcCtD
Vandetanib—Infestation—Epirubicin—sarcoma	6.69e-05	0.001	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—sarcoma	6.69e-05	0.001	CcSEcCtD
Vandetanib—Rash—Thiotepa—sarcoma	6.68e-05	0.001	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—sarcoma	6.68e-05	0.001	CcSEcCtD
Vandetanib—Dermatitis—Thiotepa—sarcoma	6.68e-05	0.001	CcSEcCtD
Vandetanib—Headache—Thiotepa—sarcoma	6.64e-05	0.000995	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—sarcoma	6.63e-05	0.000995	CcSEcCtD
Vandetanib—Rash—Dactinomycin—sarcoma	6.63e-05	0.000994	CcSEcCtD
Vandetanib—Decreased appetite—Etoposide—sarcoma	6.62e-05	0.000992	CcSEcCtD
Vandetanib—PDGFRB—lymph node—sarcoma	6.58e-05	0.00096	CbGeAlD
Vandetanib—Renal failure—Epirubicin—sarcoma	6.58e-05	0.000986	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Etoposide—sarcoma	6.57e-05	0.000985	CcSEcCtD
Vandetanib—Asthenia—Mitoxantrone—sarcoma	6.57e-05	0.000985	CcSEcCtD
Vandetanib—Fatigue—Etoposide—sarcoma	6.56e-05	0.000984	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—sarcoma	6.52e-05	0.000978	CcSEcCtD
Vandetanib—Pain—Etoposide—sarcoma	6.51e-05	0.000976	CcSEcCtD
Vandetanib—Constipation—Etoposide—sarcoma	6.51e-05	0.000976	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—sarcoma	6.5e-05	0.000975	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—sarcoma	6.5e-05	0.000975	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—sarcoma	6.49e-05	0.000973	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—sarcoma	6.49e-05	0.000973	CcSEcCtD
Vandetanib—CYP3A4—hematopoietic system—sarcoma	6.49e-05	0.000946	CbGeAlD
Vandetanib—Upper respiratory tract infection—Doxorubicin—sarcoma	6.45e-05	0.000968	CcSEcCtD
Vandetanib—Diarrhoea—Vincristine—sarcoma	6.43e-05	0.000964	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—sarcoma	6.41e-05	0.000962	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—sarcoma	6.38e-05	0.000957	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—sarcoma	6.34e-05	0.00095	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—sarcoma	6.33e-05	0.000949	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—sarcoma	6.31e-05	0.000946	CcSEcCtD
Vandetanib—Nausea—Thiotepa—sarcoma	6.29e-05	0.000944	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—sarcoma	6.28e-05	0.000942	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—sarcoma	6.28e-05	0.000941	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—sarcoma	6.26e-05	0.000939	CcSEcCtD
Vandetanib—Diarrhoea—Mitoxantrone—sarcoma	6.26e-05	0.000939	CcSEcCtD
Vandetanib—Nausea—Dactinomycin—sarcoma	6.25e-05	0.000937	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—sarcoma	6.23e-05	0.000934	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—sarcoma	6.22e-05	0.000933	CcSEcCtD
Vandetanib—Dizziness—Vincristine—sarcoma	6.21e-05	0.000932	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—sarcoma	6.19e-05	0.000928	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—sarcoma	6.19e-05	0.000928	CcSEcCtD
Vandetanib—ORM1—lymph node—sarcoma	6.17e-05	0.000901	CbGeAlD
Vandetanib—ABCC1—testis—sarcoma	6.16e-05	0.000899	CbGeAlD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	6.14e-05	0.00092	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—sarcoma	6.11e-05	0.000917	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—sarcoma	6.09e-05	0.000912	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—sarcoma	6.04e-05	0.000905	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—sarcoma	6.03e-05	0.000905	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—sarcoma	6.02e-05	0.000902	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—sarcoma	6.02e-05	0.000902	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—sarcoma	6.02e-05	0.000902	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—sarcoma	6.02e-05	0.000902	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—sarcoma	6.01e-05	0.000901	CcSEcCtD
Vandetanib—Vomiting—Vincristine—sarcoma	5.97e-05	0.000896	CcSEcCtD
Vandetanib—ABCG2—bone marrow—sarcoma	5.97e-05	0.000871	CbGeAlD
Vandetanib—Urinary tract disorder—Epirubicin—sarcoma	5.93e-05	0.000889	CcSEcCtD
Vandetanib—Rash—Vincristine—sarcoma	5.93e-05	0.000888	CcSEcCtD
Vandetanib—Dermatitis—Vincristine—sarcoma	5.92e-05	0.000888	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—sarcoma	5.9e-05	0.000885	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—sarcoma	5.89e-05	0.000883	CcSEcCtD
Vandetanib—Headache—Vincristine—sarcoma	5.89e-05	0.000883	CcSEcCtD
Vandetanib—ABL1—lymph node—sarcoma	5.87e-05	0.000856	CbGeAlD
Vandetanib—Hepatobiliary disease—Doxorubicin—sarcoma	5.85e-05	0.000878	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—sarcoma	5.84e-05	0.000876	CcSEcCtD
Vandetanib—ABCC1—liver—sarcoma	5.83e-05	0.00085	CbGeAlD
Vandetanib—Vomiting—Mitoxantrone—sarcoma	5.82e-05	0.000872	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—sarcoma	5.81e-05	0.000871	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—sarcoma	5.79e-05	0.000868	CcSEcCtD
Vandetanib—Rash—Mitoxantrone—sarcoma	5.77e-05	0.000865	CcSEcCtD
Vandetanib—Dermatitis—Mitoxantrone—sarcoma	5.77e-05	0.000864	CcSEcCtD
Vandetanib—Headache—Mitoxantrone—sarcoma	5.73e-05	0.00086	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—sarcoma	5.68e-05	0.000852	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—sarcoma	5.66e-05	0.000848	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—sarcoma	5.61e-05	0.000842	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—sarcoma	5.59e-05	0.000838	CcSEcCtD
Vandetanib—Nausea—Vincristine—sarcoma	5.58e-05	0.000837	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—sarcoma	5.57e-05	0.000836	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—sarcoma	5.56e-05	0.000833	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—sarcoma	5.49e-05	0.000823	CcSEcCtD
Vandetanib—Asthenia—Etoposide—sarcoma	5.46e-05	0.000819	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—sarcoma	5.45e-05	0.000817	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—sarcoma	5.45e-05	0.000817	CcSEcCtD
Vandetanib—Nausea—Mitoxantrone—sarcoma	5.44e-05	0.000815	CcSEcCtD
Vandetanib—ALB—lymph node—sarcoma	5.41e-05	0.00079	CbGeAlD
Vandetanib—Mediastinal disorder—Epirubicin—sarcoma	5.41e-05	0.000812	CcSEcCtD
Vandetanib—Pruritus—Etoposide—sarcoma	5.39e-05	0.000808	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—sarcoma	5.37e-05	0.000805	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—sarcoma	5.36e-05	0.000803	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—sarcoma	5.31e-05	0.000796	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—sarcoma	5.26e-05	0.000789	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—sarcoma	5.25e-05	0.000788	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—sarcoma	5.23e-05	0.000784	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—sarcoma	5.21e-05	0.000781	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—sarcoma	5.19e-05	0.000779	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—sarcoma	5.16e-05	0.000773	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—sarcoma	5.12e-05	0.000768	CcSEcCtD
Vandetanib—ABCG2—testis—sarcoma	5.1e-05	0.000744	CbGeAlD
Vandetanib—Angiopathy—Doxorubicin—sarcoma	5.04e-05	0.000756	CcSEcCtD
Vandetanib—Dizziness—Etoposide—sarcoma	5.03e-05	0.000755	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—sarcoma	5.03e-05	0.000754	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—sarcoma	5.01e-05	0.000751	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—sarcoma	4.96e-05	0.000744	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—sarcoma	4.93e-05	0.000739	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—sarcoma	4.91e-05	0.000736	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—sarcoma	4.87e-05	0.00073	CcSEcCtD
Vandetanib—Vomiting—Etoposide—sarcoma	4.84e-05	0.000726	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—sarcoma	4.84e-05	0.000725	CcSEcCtD
Vandetanib—ABCG2—liver—sarcoma	4.82e-05	0.000704	CbGeAlD
Vandetanib—Rash—Etoposide—sarcoma	4.8e-05	0.00072	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—sarcoma	4.8e-05	0.000719	CcSEcCtD
Vandetanib—Headache—Etoposide—sarcoma	4.77e-05	0.000715	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—sarcoma	4.74e-05	0.00071	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—sarcoma	4.65e-05	0.000697	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—sarcoma	4.6e-05	0.000689	CcSEcCtD
Vandetanib—Cough—Epirubicin—sarcoma	4.56e-05	0.000684	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—sarcoma	4.56e-05	0.000684	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—sarcoma	4.53e-05	0.000679	CcSEcCtD
Vandetanib—Nausea—Etoposide—sarcoma	4.52e-05	0.000678	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—sarcoma	4.51e-05	0.000677	CcSEcCtD
Vandetanib—ABCC1—lymph node—sarcoma	4.47e-05	0.000652	CbGeAlD
Vandetanib—Arthralgia—Epirubicin—sarcoma	4.45e-05	0.000667	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—sarcoma	4.45e-05	0.000667	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—sarcoma	4.44e-05	0.000665	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.42e-05	0.000663	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—sarcoma	4.35e-05	0.000653	CcSEcCtD
Vandetanib—Oedema—Epirubicin—sarcoma	4.27e-05	0.00064	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—sarcoma	4.25e-05	0.000638	CcSEcCtD
Vandetanib—Infection—Epirubicin—sarcoma	4.24e-05	0.000636	CcSEcCtD
Vandetanib—Cough—Doxorubicin—sarcoma	4.22e-05	0.000633	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—sarcoma	4.19e-05	0.000628	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—sarcoma	4.18e-05	0.000627	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—sarcoma	4.18e-05	0.000626	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—sarcoma	4.18e-05	0.000626	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—sarcoma	4.14e-05	0.000621	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—sarcoma	4.12e-05	0.000618	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—sarcoma	4.12e-05	0.000618	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—sarcoma	4.1e-05	0.000615	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.09e-05	0.000613	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—sarcoma	4.03e-05	0.000604	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—sarcoma	3.95e-05	0.000592	CcSEcCtD
Vandetanib—Infection—Doxorubicin—sarcoma	3.92e-05	0.000588	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—sarcoma	3.89e-05	0.000583	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—sarcoma	3.87e-05	0.000581	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—sarcoma	3.87e-05	0.00058	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—sarcoma	3.86e-05	0.000579	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—sarcoma	3.84e-05	0.000575	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—sarcoma	3.83e-05	0.000575	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—sarcoma	3.8e-05	0.00057	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—sarcoma	3.76e-05	0.000563	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—sarcoma	3.71e-05	0.000556	CcSEcCtD
Vandetanib—ABCG2—lymph node—sarcoma	3.7e-05	0.00054	CbGeAlD
Vandetanib—Gastrointestinal disorder—Epirubicin—sarcoma	3.68e-05	0.000552	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—sarcoma	3.68e-05	0.000552	CcSEcCtD
Vandetanib—Constipation—Epirubicin—sarcoma	3.65e-05	0.000547	CcSEcCtD
Vandetanib—Pain—Epirubicin—sarcoma	3.65e-05	0.000547	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—sarcoma	3.6e-05	0.000539	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—sarcoma	3.57e-05	0.000535	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—sarcoma	3.55e-05	0.000532	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—sarcoma	3.52e-05	0.000528	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—sarcoma	3.49e-05	0.000523	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—sarcoma	3.48e-05	0.000521	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—sarcoma	3.43e-05	0.000515	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—sarcoma	3.41e-05	0.000511	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—sarcoma	3.4e-05	0.00051	CcSEcCtD
Vandetanib—Pain—Doxorubicin—sarcoma	3.38e-05	0.000506	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—sarcoma	3.38e-05	0.000506	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—sarcoma	3.37e-05	0.000506	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—sarcoma	3.37e-05	0.000506	CcSEcCtD
Vandetanib—CYP3A4—liver—sarcoma	3.36e-05	0.00049	CbGeAlD
Vandetanib—Gastrointestinal pain—Doxorubicin—sarcoma	3.23e-05	0.000484	CcSEcCtD
Vandetanib—Abdominal pain—Doxorubicin—sarcoma	3.12e-05	0.000468	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—sarcoma	3.12e-05	0.000468	CcSEcCtD
Vandetanib—Asthenia—Epirubicin—sarcoma	3.06e-05	0.000459	CcSEcCtD
Vandetanib—Pruritus—Epirubicin—sarcoma	3.02e-05	0.000453	CcSEcCtD
Vandetanib—Diarrhoea—Epirubicin—sarcoma	2.92e-05	0.000438	CcSEcCtD
Vandetanib—Asthenia—Doxorubicin—sarcoma	2.83e-05	0.000425	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—sarcoma	2.82e-05	0.000423	CcSEcCtD
Vandetanib—Pruritus—Doxorubicin—sarcoma	2.79e-05	0.000419	CcSEcCtD
Vandetanib—Vomiting—Epirubicin—sarcoma	2.71e-05	0.000407	CcSEcCtD
Vandetanib—Diarrhoea—Doxorubicin—sarcoma	2.7e-05	0.000405	CcSEcCtD
Vandetanib—Rash—Epirubicin—sarcoma	2.69e-05	0.000403	CcSEcCtD
Vandetanib—Dermatitis—Epirubicin—sarcoma	2.69e-05	0.000403	CcSEcCtD
Vandetanib—Headache—Epirubicin—sarcoma	2.67e-05	0.000401	CcSEcCtD
Vandetanib—Dizziness—Doxorubicin—sarcoma	2.61e-05	0.000391	CcSEcCtD
Vandetanib—Nausea—Epirubicin—sarcoma	2.53e-05	0.00038	CcSEcCtD
Vandetanib—Vomiting—Doxorubicin—sarcoma	2.51e-05	0.000376	CcSEcCtD
Vandetanib—Rash—Doxorubicin—sarcoma	2.49e-05	0.000373	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—sarcoma	2.49e-05	0.000373	CcSEcCtD
Vandetanib—Headache—Doxorubicin—sarcoma	2.47e-05	0.000371	CcSEcCtD
Vandetanib—Nausea—Doxorubicin—sarcoma	2.35e-05	0.000352	CcSEcCtD
Vandetanib—MAP2K5—Signaling Pathways—SRC—sarcoma	1.85e-06	1.54e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CREB1—sarcoma	1.85e-06	1.54e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—SRC—sarcoma	1.84e-06	1.53e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—TP53—sarcoma	1.84e-06	1.53e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MDM2—sarcoma	1.82e-06	1.51e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—CTNNB1—sarcoma	1.82e-06	1.51e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—MYC—sarcoma	1.81e-06	1.51e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CCND1—sarcoma	1.81e-06	1.5e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FOXO1—sarcoma	1.81e-06	1.5e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CREB1—sarcoma	1.81e-06	1.5e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PDGFRB—sarcoma	1.81e-06	1.5e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—JUN—sarcoma	1.81e-06	1.5e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—SRC—sarcoma	1.81e-06	1.5e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—SRC—sarcoma	1.8e-06	1.5e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—VEGFA—sarcoma	1.8e-06	1.5e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—SRC—sarcoma	1.8e-06	1.49e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL2—sarcoma	1.79e-06	1.49e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CTNNB1—sarcoma	1.79e-06	1.49e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—HRAS—sarcoma	1.79e-06	1.49e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—HRAS—sarcoma	1.79e-06	1.49e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KRAS—sarcoma	1.79e-06	1.49e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—HRAS—sarcoma	1.79e-06	1.49e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—SRC—sarcoma	1.78e-06	1.48e-05	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—HRAS—sarcoma	1.78e-06	1.48e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CREB1—sarcoma	1.78e-06	1.48e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—NRAS—sarcoma	1.78e-06	1.48e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PDGFRA—sarcoma	1.78e-06	1.48e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—SRC—sarcoma	1.78e-06	1.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—NRAS—sarcoma	1.77e-06	1.47e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—EGFR—sarcoma	1.77e-06	1.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL2—sarcoma	1.76e-06	1.46e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—HRAS—sarcoma	1.76e-06	1.46e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—VEGFA—sarcoma	1.76e-06	1.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KDR—sarcoma	1.76e-06	1.46e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MDM2—sarcoma	1.75e-06	1.46e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CCND1—sarcoma	1.75e-06	1.45e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—JUN—sarcoma	1.75e-06	1.45e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—VEGFA—sarcoma	1.74e-06	1.44e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—NRAS—sarcoma	1.74e-06	1.44e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—NRAS—sarcoma	1.73e-06	1.44e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CTNNB1—sarcoma	1.73e-06	1.44e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—NRAS—sarcoma	1.73e-06	1.44e-05	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—HRAS—sarcoma	1.72e-06	1.43e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—NRAS—sarcoma	1.72e-06	1.43e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—JUN—sarcoma	1.71e-06	1.42e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—NRAS—sarcoma	1.71e-06	1.42e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—HRAS—sarcoma	1.7e-06	1.42e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—SRC—sarcoma	1.7e-06	1.41e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CTNNB1—sarcoma	1.7e-06	1.41e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL2—sarcoma	1.7e-06	1.41e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KDR—sarcoma	1.69e-06	1.41e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—SRC—sarcoma	1.69e-06	1.4e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—MDM2—sarcoma	1.68e-06	1.4e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KRAS—sarcoma	1.67e-06	1.39e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CTNNB1—sarcoma	1.66e-06	1.38e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—MYC—sarcoma	1.66e-06	1.38e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—JUN—sarcoma	1.65e-06	1.37e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—VEGFA—sarcoma	1.64e-06	1.37e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—SRC—sarcoma	1.64e-06	1.36e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—NRAS—sarcoma	1.64e-06	1.36e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CTNNB1—sarcoma	1.64e-06	1.36e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—NRAS—sarcoma	1.62e-06	1.35e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—EGFR—sarcoma	1.62e-06	1.35e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—SRC—sarcoma	1.62e-06	1.35e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KIT—sarcoma	1.62e-06	1.34e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—NRAS—sarcoma	1.62e-06	1.34e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—EGFR—sarcoma	1.62e-06	1.34e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—MYC—sarcoma	1.62e-06	1.34e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—MYC—sarcoma	1.6e-06	1.33e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—HRAS—sarcoma	1.58e-06	1.32e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—EGFR—sarcoma	1.58e-06	1.31e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—EGFR—sarcoma	1.58e-06	1.31e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—NRAS—sarcoma	1.58e-06	1.31e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—EGFR—sarcoma	1.57e-06	1.31e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CTNNB1—sarcoma	1.57e-06	1.3e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SRC—sarcoma	1.57e-06	1.3e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—EGFR—sarcoma	1.56e-06	1.3e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—NRAS—sarcoma	1.56e-06	1.3e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KIT—sarcoma	1.56e-06	1.29e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—EGFR—sarcoma	1.56e-06	1.29e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MDM2—sarcoma	1.55e-06	1.29e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CREB1—sarcoma	1.54e-06	1.28e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—SRC—sarcoma	1.54e-06	1.28e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KRAS—sarcoma	1.53e-06	1.27e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MDM2—sarcoma	1.53e-06	1.27e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KRAS—sarcoma	1.53e-06	1.27e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—MYC—sarcoma	1.53e-06	1.27e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—sarcoma	1.52e-06	1.27e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—HRAS—sarcoma	1.52e-06	1.26e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CTNNB1—sarcoma	1.51e-06	1.26e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—NRAS—sarcoma	1.51e-06	1.25e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SRC—sarcoma	1.5e-06	1.25e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2—sarcoma	1.5e-06	1.25e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KDR—sarcoma	1.5e-06	1.24e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MDM2—sarcoma	1.5e-06	1.24e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—KRAS—sarcoma	1.49e-06	1.24e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KRAS—sarcoma	1.49e-06	1.24e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—EGFR—sarcoma	1.49e-06	1.24e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TP53—sarcoma	1.49e-06	1.24e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KRAS—sarcoma	1.49e-06	1.24e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CREB1—sarcoma	1.48e-06	1.23e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—SRC—sarcoma	1.48e-06	1.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—NRAS—sarcoma	1.48e-06	1.23e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KRAS—sarcoma	1.48e-06	1.23e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MDM2—sarcoma	1.47e-06	1.22e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—KRAS—sarcoma	1.47e-06	1.22e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—MYC—sarcoma	1.47e-06	1.22e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—JUN—sarcoma	1.46e-06	1.21e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—MYC—sarcoma	1.45e-06	1.21e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CTNNB1—sarcoma	1.45e-06	1.2e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—NRAS—sarcoma	1.45e-06	1.2e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—EGFR—sarcoma	1.44e-06	1.2e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HRAS—sarcoma	1.42e-06	1.18e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—NRAS—sarcoma	1.42e-06	1.18e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—EGFR—sarcoma	1.42e-06	1.18e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—SRC—sarcoma	1.42e-06	1.18e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KRAS—sarcoma	1.41e-06	1.17e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—MYC—sarcoma	1.4e-06	1.17e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—KRAS—sarcoma	1.4e-06	1.16e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—KRAS—sarcoma	1.39e-06	1.16e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KIT—sarcoma	1.38e-06	1.15e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—EGFR—sarcoma	1.37e-06	1.14e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2—sarcoma	1.37e-06	1.14e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—SRC—sarcoma	1.37e-06	1.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—NRAS—sarcoma	1.36e-06	1.13e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TP53—sarcoma	1.36e-06	1.13e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—KRAS—sarcoma	1.36e-06	1.13e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—MYC—sarcoma	1.35e-06	1.12e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KRAS—sarcoma	1.34e-06	1.11e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CTNNB1—sarcoma	1.34e-06	1.11e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2—sarcoma	1.34e-06	1.11e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CCND1—sarcoma	1.33e-06	1.11e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—JUN—sarcoma	1.33e-06	1.1e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TP53—sarcoma	1.33e-06	1.1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	1.32e-06	1.1e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—EGFR—sarcoma	1.32e-06	1.1e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2—sarcoma	1.32e-06	1.09e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—NRAS—sarcoma	1.31e-06	1.09e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CREB1—sarcoma	1.31e-06	1.09e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TP53—sarcoma	1.31e-06	1.09e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ENO2—sarcoma	1.31e-06	1.09e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CCND1—sarcoma	1.3e-06	1.08e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HBA1—sarcoma	1.3e-06	1.08e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HRAS—sarcoma	1.3e-06	1.08e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—JUN—sarcoma	1.3e-06	1.08e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—HRAS—sarcoma	1.3e-06	1.08e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—EGFR—sarcoma	1.3e-06	1.08e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KRAS—sarcoma	1.3e-06	1.08e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CTNNB1—sarcoma	1.29e-06	1.07e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CCND1—sarcoma	1.28e-06	1.07e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—JUN—sarcoma	1.28e-06	1.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MDM2—sarcoma	1.27e-06	1.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KRAS—sarcoma	1.27e-06	1.06e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CTNNB1—sarcoma	1.27e-06	1.06e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—HRAS—sarcoma	1.27e-06	1.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—MYC—sarcoma	1.27e-06	1.06e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HRAS—sarcoma	1.27e-06	1.05e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—HRAS—sarcoma	1.26e-06	1.05e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—NRAS—sarcoma	1.26e-06	1.05e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HRAS—sarcoma	1.26e-06	1.04e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—HRAS—sarcoma	1.25e-06	1.04e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KRAS—sarcoma	1.25e-06	1.03e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—TP53—sarcoma	1.24e-06	1.03e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MDM2—sarcoma	1.23e-06	1.02e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—KRAS—sarcoma	1.23e-06	1.02e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—MYC—sarcoma	1.22e-06	1.02e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—HRAS—sarcoma	1.2e-06	9.96e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—EGFR—sarcoma	1.2e-06	9.95e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TP53—sarcoma	1.19e-06	9.91e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SRC—sarcoma	1.19e-06	9.91e-06	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—HRAS—sarcoma	1.19e-06	9.87e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HRAS—sarcoma	1.18e-06	9.83e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—KRAS—sarcoma	1.17e-06	9.75e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SRC—sarcoma	1.17e-06	9.7e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—NRAS—sarcoma	1.16e-06	9.67e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	1.16e-06	9.65e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—HRAS—sarcoma	1.15e-06	9.6e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TP53—sarcoma	1.15e-06	9.57e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SRC—sarcoma	1.15e-06	9.55e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—EGFR—sarcoma	1.15e-06	9.54e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRAS—sarcoma	1.15e-06	9.53e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HRAS—sarcoma	1.14e-06	9.48e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2—sarcoma	1.14e-06	9.45e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—sarcoma	1.14e-06	9.45e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—KRAS—sarcoma	1.13e-06	9.4e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRAS—sarcoma	1.12e-06	9.33e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—sarcoma	1.12e-06	9.3e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLCG1—sarcoma	1.11e-06	9.24e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CCND1—sarcoma	1.11e-06	9.22e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JUN—sarcoma	1.11e-06	9.2e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRAS—sarcoma	1.11e-06	9.19e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HRAS—sarcoma	1.1e-06	9.15e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CTNNB1—sarcoma	1.1e-06	9.13e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2—sarcoma	1.1e-06	9.11e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MDM2—sarcoma	1.09e-06	9.03e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—KRAS—sarcoma	1.08e-06	9.01e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—MYC—sarcoma	1.08e-06	9.01e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—HRAS—sarcoma	1.08e-06	8.98e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CCND1—sarcoma	1.07e-06	8.88e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—MYC—sarcoma	1.07e-06	8.88e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JUN—sarcoma	1.07e-06	8.86e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—EGFR—sarcoma	1.06e-06	8.81e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—HRAS—sarcoma	1.06e-06	8.8e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CTNNB1—sarcoma	1.06e-06	8.8e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—MYC—sarcoma	1.05e-06	8.69e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—EGFR—sarcoma	1.04e-06	8.68e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—HRAS—sarcoma	1.04e-06	8.65e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—MYC—sarcoma	1.03e-06	8.56e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—EGFR—sarcoma	1.02e-06	8.5e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—EGFR—sarcoma	1.01e-06	8.37e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—KRAS—sarcoma	1e-06	8.32e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—HRAS—sarcoma	9.98e-07	8.29e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SRC—sarcoma	9.93e-07	8.25e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KRAS—sarcoma	9.87e-07	8.2e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2—sarcoma	9.71e-07	8.07e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—sarcoma	9.67e-07	8.03e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KRAS—sarcoma	9.66e-07	8.03e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—HRAS—sarcoma	9.62e-07	7.99e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SRC—sarcoma	9.57e-07	7.95e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRAS—sarcoma	9.55e-07	7.94e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KRAS—sarcoma	9.51e-07	7.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CCND1—sarcoma	9.46e-07	7.86e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JUN—sarcoma	9.44e-07	7.85e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CTNNB1—sarcoma	9.37e-07	7.79e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—sarcoma	9.32e-07	7.74e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—HRAS—sarcoma	9.22e-07	7.66e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRAS—sarcoma	9.2e-07	7.65e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—MYC—sarcoma	8.9e-07	7.39e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TP53—sarcoma	8.77e-07	7.29e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TP53—sarcoma	8.59e-07	7.14e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—MYC—sarcoma	8.57e-07	7.12e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—HRAS—sarcoma	8.51e-07	7.07e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TP53—sarcoma	8.46e-07	7.03e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HRAS—sarcoma	8.39e-07	6.97e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—EGFR—sarcoma	8.39e-07	6.97e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—sarcoma	8.25e-07	6.85e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KRAS—sarcoma	8.22e-07	6.83e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HRAS—sarcoma	8.21e-07	6.83e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRAS—sarcoma	8.15e-07	6.77e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HRAS—sarcoma	8.09e-07	6.72e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KRAS—sarcoma	7.92e-07	6.58e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—MYC—sarcoma	7.59e-07	6.31e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—EGFR—sarcoma	7.42e-07	6.17e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TP53—sarcoma	7.31e-07	6.07e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TP53—sarcoma	7.04e-07	5.85e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KRAS—sarcoma	7.01e-07	5.83e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HRAS—sarcoma	6.99e-07	5.81e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HRAS—sarcoma	6.73e-07	5.6e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TP53—sarcoma	6.23e-07	5.18e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HRAS—sarcoma	5.96e-07	4.95e-06	CbGpPWpGaD
